These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38053317)

  • 41. Clinical impact of a cancer genomic profiling test using an in-house comprehensive targeted sequencing system.
    Hayashi H; Tanishima S; Fujii K; Mori R; Okada C; Yanagita E; Shibata Y; Matsuoka R; Amano T; Yamada T; Yabe I; Kinoshita I; Komatsu Y; Dosaka-Akita H; Nishihara H
    Cancer Sci; 2020 Oct; 111(10):3926-3937. PubMed ID: 32772458
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
    Paolillo C; Londin E; Fortina P
    Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers.
    Wilson TR; Udyavar AR; Chang CW; Spoerke JM; Aimi J; Savage HM; Daemen A; O'Shaughnessy JA; Bourgon R; Lackner MR
    Mol Cancer Res; 2019 Jan; 17(1):97-108. PubMed ID: 30171174
    [TBL] [Abstract][Full Text] [Related]  

  • 44. DNA damage response proteins in canine cancer as potential research targets in comparative oncology.
    Hernández-Suárez B; Gillespie DA; Pawlak A
    Vet Comp Oncol; 2022 Jun; 20(2):347-361. PubMed ID: 34923737
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recurrent gene mutations detected in canine mast cell tumours by next generation sequencing.
    Vozdova M; Kubickova S; Pal K; Fröhlich J; Fictum P; Rubes J
    Vet Comp Oncol; 2020 Dec; 18(4):509-518. PubMed ID: 31999054
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
    Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC
    Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Validation of a Multiplexed Gene Signature Assay for Diagnosis of Canine Cancers from Formalin-Fixed Paraffin-Embedded Tissues.
    Davis B; Schwartz M; Duchemin D; Carl Barrett J; Post G
    J Vet Intern Med; 2017 May; 31(3):854-863. PubMed ID: 28370296
    [TBL] [Abstract][Full Text] [Related]  

  • 49. General assessment of copy number variation in normal and tumor tissues of the domestic dog (Canis lupus familiaris).
    Gurgul A; Żukowski K; Ślaska B; Semik E; Pawlina K; Ząbek T; Jasielczuk I; Bugno-Poniewierska M
    J Appl Genet; 2014 Aug; 55(3):353-63. PubMed ID: 24573641
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Copy number alteration signatures as biomarkers in cancer: a review.
    Giles Doran C; Pennington SR
    Biomark Med; 2022 Apr; 16(5):371-386. PubMed ID: 35195030
    [TBL] [Abstract][Full Text] [Related]  

  • 51. On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients.
    Schwaederle M; Daniels GA; Piccioni DE; Fanta PT; Schwab RB; Shimabukuro KA; Parker BA; Kurzrock R
    Mol Cancer Ther; 2015 Jun; 14(6):1488-94. PubMed ID: 25852059
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Findings from precision oncology in the clinic: rare, novel variants are a significant contributor to scaling molecular diagnostics.
    Doig KD; Love CG; Conway T; Seleznev A; Ma D; Fellowes A; Blombery P; Fox SB
    BMC Med Genomics; 2022 Mar; 15(1):70. PubMed ID: 35346197
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Implementing precision cancer medicine in the genomic era.
    Chen HZ; Bonneville R; Roychowdhury S
    Semin Cancer Biol; 2019 Apr; 55():16-27. PubMed ID: 29857039
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection.
    Cani AK; Dolce EM; Darga EP; Hu K; Liu CJ; Pierce J; Bradbury K; Kilgour E; Aung K; Schiavon G; Carroll D; Carr TH; Klinowska T; Lindemann J; Marshall G; Rowlands V; Harrington EA; Barrett JC; Sathiyayogan N; Morrow C; Sero V; Armstrong AC; Baird R; Hamilton E; Im SA; Jhaveri K; Patel MR; Dive C; Tomlins SA; Udager AM; Hayes DF; Paoletti C
    Mol Oncol; 2022 May; 16(10):1969-1985. PubMed ID: 34866317
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Integrative omics analyses broaden treatment targets in human cancer.
    Sengupta S; Sun SQ; Huang KL; Oh C; Bailey MH; Varghese R; Wyczalkowski MA; Ning J; Tripathi P; McMichael JF; Johnson KJ; Kandoth C; Welch J; Ma C; Wendl MC; Payne SH; Fenyö D; Townsend RR; Dipersio JF; Chen F; Ding L
    Genome Med; 2018 Jul; 10(1):60. PubMed ID: 30053901
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Concordance Study of a 520-Gene Next-Generation Sequencing-Based Genomic Profiling Assay of Tissue and Plasma Samples.
    Wang M; Chen X; Dai Y; Wu D; Liu F; Yang Z; Song B; Xie L; Yang L; Zhao W; Zhang C; Shen W; Fan C; Teng C; Zhao X; Gao N; Shang D; Zhao G; Xin T
    Mol Diagn Ther; 2022 May; 26(3):309-322. PubMed ID: 35305253
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical Genomic Profiling of a Diverse Array of Oncology Specimens at a Large Academic Cancer Center: Identification of Targetable Variants and Experience with Reimbursement.
    Sireci AN; Aggarwal VS; Turk AT; Gindin T; Mansukhani MM; Hsiao SJ
    J Mol Diagn; 2017 Mar; 19(2):277-287. PubMed ID: 28024947
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Data resources for the identification and interpretation of actionable mutations by clinicians.
    Prawira A; Pugh TJ; Stockley TL; Siu LL
    Ann Oncol; 2017 May; 28(5):946-957. PubMed ID: 28327901
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review.
    Syn NL; Yong WP; Goh BC; Lee SC
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):911-22. PubMed ID: 27249175
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors.
    Ramkissoon SH; Bandopadhayay P; Hwang J; Ramkissoon LA; Greenwald NF; Schumacher SE; O'Rourke R; Pinches N; Ho P; Malkin H; Sinai C; Filbin M; Plant A; Bi WL; Chang MS; Yang E; Wright KD; Manley PE; Ducar M; Alexandrescu S; Lidov H; Delalle I; Goumnerova LC; Church AJ; Janeway KA; Harris MH; MacConaill LE; Folkerth RD; Lindeman NI; Stiles CD; Kieran MW; Ligon AH; Santagata S; Dubuc AM; Chi SN; Beroukhim R; Ligon KL
    Neuro Oncol; 2017 Jul; 19(7):986-996. PubMed ID: 28104717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.